

# Benchmark Botanics Reports Q1 2020 Results

Vancouver, British Columbia--(Newsfile Corp. - June 1, 2020) - **Benchmark Botanics, Inc. (CSE: BBT) ("Benchmark" or the "Company")** a cannabis producer, today released its financial and operational results for the first quarter ended March 31, 2020.

## HIGHLIGHTS FOR THE THREE MONTHS ENDED MARCH 31, 2020

- **Achieved record quarterly revenue of \$191,095**
- **Completed a \$1,700,000 Private Placement Financing**

Our complete financial statements and associated management discussion and analysis can be found on SEDAR.

## RESULTS OF OPERATIONS

The following table sets forth consolidated statements of operations, which is expressed in Canadian dollars, except share and per share amounts, for the indicated periods.

	Three-Month Period Ended (Unaudited)	
	3/31/2020	3/31/2019
Revenue	191,095	-
Gross profit before fair value impacts in cost of sales	89,189	-
Gross profit	47,739	127,862
Gross margin before fair value impacts in cost of sales	56.4%	-
Operating expenses	943,102	1,503,637
Loss from operations	(895,363)	(1,375,775)
Other income (expense)	23,015	3,474
Net loss	(872,348)	(1,372,301)
EBITDA	(789,577)	(1,275,353)
Adjusted EBITDA	(723,304)	(1,016,338)
Loss per share		
Basic	(0.005)	(0.010)
Weighted average number of shares		
Basic	172,517,023	142,576,705

Total revenue for the three months ended March 31, 2020 was \$191,095 (2019 - \$nil) from sales of dried cannabis to a licensed producer and retail sales for the adult-use market in Canada. The total quantity of cannabis sold during the three months ended March 31, 2020 was 29,587 grams (2019 - nil) at an average sale price of \$6.46.

"Benchmark continued to grow during Q1 2020. We look forward to continuing to grow revenue and expect 2020 to be a very exciting year for our stakeholders. We have assembled a high-caliber team that is executing on the opportunities ahead. I am excited to see the commitment to drive strong revenue growth coupled with profitability. With the global impact from the COVID-19 pandemic in the quarter we acted promptly and remain operational while adjusting our priorities and spending to appropriately reflect the anticipated revenue impact. The health of all our staff and their families remain a priority for us in this challenging time and as we emerge from the pandemic, we will continue to provide support for their wellbeing and for our community," said William Ying, Benchmark Botanics CEO.

## About Benchmark Botanics Inc.

Benchmark is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical, pharmaceutical and recreational markets in Canada. The Company's business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp throughout Asia, in countries where it is legal to do so.

Benchmark is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company's global footprint.

Benchmark's 100% owned subsidiary, Potanicals Green Growers Inc. ("Potanicals") is a Health Canada licensed producer under the Cannabis Act and its regulations. The Company is producing at its indoor Peachland, BC Cannabis Complex and is constructing a Phase II expansion of an additional 10,000 square foot extraction facility there. Along with cultivation and production, the company's Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetic improvements and is progressing towards CBD oil extraction and an EU-GMP certification.

As part of its expansion strategy, the company and a joint venture partner completed a second facility, a 4-acre Greenhouse Operation in Pitt Meadows, BC. The Company, through Potanicals, has received its second cultivation license, effective

November 29, 2019, from Health Canada for the Pitt Meadow greenhouse.

For further information, please visit the Company's website at [www.benchmarkbotanics.com](http://www.benchmarkbotanics.com) or the Company's profile at [www.sedar.com](http://www.sedar.com).

If you would like to be added to Benchmark's news distribution list, please sign up at Investor Relations [info@bbtinc.ca](mailto:info@bbtinc.ca)

ON BEHALF OF THE BOARD OF  
**BENCHMARK BOTANICS INC.**

/s/ "William Ying"  
William Ying  
Chief Executive Officer

Tel: 604-238-0005  
[www.benchmarkbotanics.com](http://www.benchmarkbotanics.com)

*The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.*

#### FORWARD LOOKING INFORMATION

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.



**BENCHMARK**  
BOTANICS INC.

To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/57062>